Amgen, Servier deal

Servier granted Amgen U.S. commercialization rights to Servier's cardiovascular drug Procoralan ivabradine. The selective and specific If channel inhibitor is marketed in 100 countries, excluding the U.S., to treat stable angina and in the EU to treat chronic heart failure (CHF). Servier will receive $50 million up front and is eligible for undisclosed milestones, plus royalties. Amgen said it believes the current data package for ivabradine could support the indications in the U.S. and said it will discuss potential submissions with FDA. ...